Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Ondansetron

Preparation Calculator

USE IF: Nausea/vomiting (post-op, acute care, CINV/RINV pathways, selected gastroenteritis support) when benefits outweigh QT/hepatic risk.

AVOID IF: Apomorphine co-therapy; congenital long QT or mandated QT-unsafe context; known hypersensitivity.

Ondansetron

5-HT3 antagonist antiemetic

AdultPediatricsAntiemeticPost-opOncologyGI

Indication

Nausea/vomiting • postop N/V • chemotherapy/radiation-associated N/V • gastroenteritis support

At a glance

INDICATIONS (CORE USE)

Acute nausea/vomiting Postoperative nausea/vomiting Chemotherapy- or radiation-induced nausea/vomiting Selected gastroenteritis support (when facilitating intake/hydration)

ADULT DOSE (STANDARD)

PO/ODT/IV commonly 4–8 mg depending on indication. Post-op / acute ED: often **4 mg IV** when IV route is chosen. CINV/RINV: follow emetogenic-risk pathways (may allow higher scheduled/regimen doses per protocol).

MAX DOSE

Indication-dependent; **hepatic impairment reduces safe ceiling** (commonly **≤8 mg/day** total exposure or per label—confirm locally). Avoid stacking QT-active drugs without ECG/electrolyte plan.

Route

PO / ODT / IV

PEDIATRIC DOSE

Weight- or protocol-based dosing only — confirm pediatric reference; apply hepatic ceiling and QT-risk review when relevant.

Do not miss

Must-not-miss safety points

Major warning

- QT prolongation / arrhythmia risk - Correct K / Mg abnormalities if clinically relevant - Avoid in congenital long QT or major QT-prolonging combinations when alternatives are suitable - Severe hepatic impairment lowers safe dose ceiling

Indications

USE IF: acute or postoperative N/V, CINV/RINV per pathway, or selected gastroenteritis when antiemesis supports hydration/oral intake. AVOID IF: apomorphine combination, high-risk QT context where alternatives are safer, or hypersensitivity.

Primary

  • Acute nausea/vomiting
  • Postoperative nausea/vomiting
  • Chemotherapy-induced nausea/vomiting
  • Radiation-associated nausea/vomiting

Secondary

  • Gastroenteritis-associated nausea when oral rehydration / intake is being facilitated

Dosing

STANDARD (ADULT PO)

ED/post-op: IV ondansetron is commonly **4 mg** for adult antiemesis when appropriate. Oral/ODT: **4–8 mg** is a common starting range by indication and local protocol.

ADULT DOSE

**4 mg IV** for many acute/postoperative adult scenarios when IV is chosen. **4–8 mg PO or ODT** for oral routes depending on indication. CINV: use **institutional emetogenic-risk pathways** (doses/schedules may exceed single acute doses).

PEDIATRIC DOSE

Institutional / pediatric reference dosing only (weight- or BSA-based).

MAX DOSE

Do not exceed **hepatic-adjusted** exposure limits; many references cite **≤8 mg/day** in moderate–severe hepatic impairment (confirm label).

Practical Note

**ODT** when vomiting limits swallowing standard tablets. Do not let antiemetic response falsely reassure against obstruction / surgical abdomen.

Warnings

Clinical warnings

  • - QT prolongation / torsades risk
  • - Serotonin syndrome risk in combination context (rare, clinically relevant)
  • - Constipation / headache (common, usually secondary)
  • - Congenital long QT / major QT-risk combinations → use caution or avoid when alternatives are suitable

Adverse effects

  • - Headache, constipation, dizziness
  • - Transient liver enzyme elevations (uncommon)
  • - QT prolongation (dose- and risk-factor dependent)

Contraindications

  • - Known hypersensitivity to ondansetron
  • - Concomitant apomorphine

Drug interactions

  • - Other QT-prolonging drugs → additive QT / torsades risk
  • - Apomorphine — contraindicated combination with ondansetron
  • - Serotonergic co-therapy — monitor for serotonin excess when clinically relevant (contribution uncertain)

Special populations

Pediatrics

Weight- or protocol-based dosing only — confirm pediatric reference; apply hepatic ceiling and QT-risk review when relevant.

Pregnancy

Pregnancy: use only when clearly needed; follow obstetric / formulary guidance.

Lactation

small amounts may enter milk; risk/benefit with infant feeding plan.

Renal impairment

Renal impairment: generally less dose adjustment than hepatic; still mind QT co-factors and polypharmacy.

Hepatic impairment

**Lower daily ceiling** (often **≤8 mg/day** total ondansetron exposure in significant hepatic impairment per label—confirm). Avoid additional QT stressors without monitoring.

Elderly

Higher sensitivity to QT and CNS effects — prefer lowest effective dose; monitor ECG/electrolytes when risk is not trivial.

Administration

IV: **slow push or short infusion** per product labeling / pharmacy protocol (avoid rapid bolus in QT-vulnerable patients). ODT: place on tongue to dissolve when oral solids are poorly tolerated.

Monitoring

  • Monitor: - Symptoms / response - Electrolytes if QT risk or major vomiting losses - ECG / QT only in clinically relevant risk settings
  • Recheck: - If repeated dosing, ongoing vomiting, or high-risk QT context — reassess
  • Hold if:
    - Significant QT prolongation / arrhythmic concern
    - Severe hypersensitivity

Overdose / toxicity

Clinical Picture

Exaggerated antiemetic adverse effects; **QT / rhythm concerns**; possible **CNS** symptoms if relevant.

Immediate Actions

**Stop drug**; supportive care; **ECG** and **electrolyte correction** if indicated.

Antidote

**No specific antidote** — supportive care.

Decontamination

Large oral ingestion: supportive care; contact toxicology if massive exposure or concerning symptoms.

Escalation

**Severe arrhythmia** → ACLS / emergency cardiology management per protocol.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Match route and dose to **indication and QT/hepatic risk**. Post-op/ED often **4 mg IV**; CINV follows **emetogenic-risk tables**.

Clinical pearls

- **ODT** when vomiting limits tablet swallowing. - **QT context matters** — electrolytes, co-meds, and ECG when risk is real. - **Hepatic impairment lowers the safe daily ceiling** — confirm local limits.

Pharmacy Tool

Preparation Calculator

Ondansetron 1 mg/mL oral solution

solution · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

Hepatic metabolism (CYP-mediated) with **reduced clearance in hepatic impairment**; renal elimination of metabolites — clinically less dose-limiting than liver in most adults.

Mechanism of action

Selective **5-HT3 receptor antagonism** in the gut and CNS chemoreceptor trigger zone → reduced vagal afferent signaling and reduced CTZ activation.

Common brand names

Saudi Arabia

Zofran, Ondemet

Global

Zuplenz, Zuplenz (ODT example), (placeholder — verify local formulation)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • **CINV/RINV** regimens are **protocol- and emetogenic-risk–driven** — verify institutional pathway and premedications.
  • **QT risk** rises with **electrolyte loss**, **polypharmacy**, and **hepatic impairment** — dose and monitor accordingly.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • NCCN / ASCO antiemesis and supportive care guidance (where applicable)
  • ASA / institutional perioperative nausea/vomiting protocols
  • FDA / SFDA product labeling
  • Local oncology / pharmacy CINV pathways
  • NCCN / ASCO antiemesis and supportive care guidance (where applicable)
  • ASA / institutional perioperative nausea/vomiting protocols
  • FDA / SFDA product labeling
  • Local oncology / pharmacy CINV pathways